Skip to content

ANTIVIRAL TECHNOLOGIES, INC.: 10-K filed 2013-03-26

What ANTIVIRAL TECHNOLOGIES, INC. reported in its annual report filed 2013-03-26 (fiscal FY 2012): 19 published measures, 45 facts as tagged in accession 0001137050-13-000127.

This filing

Form
10-K (annual report)
Filed
2013-03-26
Fiscal period
fiscal FY 2012
Accession
0001137050-13-000127 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; a measure with a published history links to it, and the history shows the latest-filed value per period. All ANTIVIRAL TECHNOLOGIES, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2012-12-31485,196USD
At 2011-12-31405,555USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2012-12-312,787,712USD
At 2011-12-312,339,350USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2012-12-31-2,302,516USD
At 2011-12-31-1,933,795USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2012-12-31699USD
At 2011-12-313,935USD
At 2010-12-313,134USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2012-01-01 to 2012-12-31-363,282USD366
2007-09-13 to 2012-12-31-2,299,338USD1937
2011-01-01 to 2011-12-31-402,884USD365

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2012-01-01 to 2012-12-31-139,177USD366
2007-09-13 to 2012-12-31-1,207,285USD1937
2011-01-01 to 2011-12-31-138,489USD365

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2012-01-01 to 2012-12-31244,403USD366
2007-09-13 to 2012-12-311,789,211USD1937
2011-01-01 to 2011-12-31195,359USD365

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2012-01-01 to 2012-12-31-103,109USD366
2007-09-13 to 2012-12-31-556,711USD1937
2011-01-01 to 2011-12-31-49,162USD365

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2012-12-311,603USD
At 2011-12-312,890USD

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2012-12-31701USD
At 2011-12-314,881USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

PeriodValueUnitDays
2007-09-13 to 2012-12-31-31,962USD1937

Net finite-lived intangible assets

Finite-lived intangible assets after amortization. This excludes goodwill and should not be combined with indefinite-lived intangible assets without checking scope.

PeriodValueUnitDays
At 2012-12-31482,892USD
At 2011-12-31397,784USD

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2012-12-31-144,858USD
At 2011-12-31-144,858USD

Accumulated other comprehensive income or loss

Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.

PeriodValueUnitDays
At 2012-12-31-8,320USD
At 2011-12-31-2,881USD

Gross property, plant and equipment

Cost of property, plant and equipment before accumulated depreciation. Historical cost does not indicate current value or replacement cost.

PeriodValueUnitDays
At 2012-12-3110,886USD
At 2011-12-3110,836USD

Accumulated depreciation on property, plant and equipment

Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.

PeriodValueUnitDays
At 2012-12-31-9,283USD
At 2011-12-31-7,946USD

Comprehensive income or loss

Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.

PeriodValueUnitDays
2012-01-01 to 2012-12-31-368,721USD366
2007-09-13 to 2012-12-31-2,307,658USD1937
2011-01-01 to 2011-12-31-409,909USD365

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2012-01-01 to 2012-12-31356,438USD366
2007-09-13 to 2012-12-312,128,392USD1937
2011-01-01 to 2011-12-31394,019USD365

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

PeriodValueUnitDays
2012-01-01 to 2012-12-311,305USD366
2007-09-13 to 2012-12-319,133USD1937
2011-01-01 to 2011-12-311,284USD365

Inspect the source

Entity
ANTIVIRAL TECHNOLOGIES, INC. / CIK 0001445226
Captured
SEC response SHA-256
8eebaa08a3fdfe2277d78068fe27fc31b233085f2e48bbd10b68292209892301

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001445226.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))